What is it about?
The new 2023 ACR/EULAR criteria for antiphospholipid syndrome are more specific but miss many patients—especially those with pregnancy issues or certain antibodies—raising concerns about their real-world use.
Featured Image
Read the Original
This page is a summary of: Assessment of 2023 ACR/EULAR antiphospholipid syndrome classification criteria in a Spanish cohort, Clinical Chemistry and Laboratory Medicine (CCLM), July 2025, De Gruyter,
DOI: 10.1515/cclm-2025-0508.
You can read the full text:
Contributors
Be the first to contribute to this page
